Literature DB >> 9249563

Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II.

A Oyekan1, M Balazy, J C McGiff.   

Abstract

In the rat isolated perfused kidney, 5,8,11,14-eicosatetraynoic acid, an inhibitor of all pathways of arachidonic acid (AA) metabolism, diminished endothelin-1 (ET-1)- and angiotensin II (ANG II)-induced renal vasoconstriction by approximately 60-70%. We then examined the individual contribution of each oxygenase, cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P-450 (CYP) to the vasoconstrictor effects of ET-1 and ANG II. Inhibition of COX with indomethacin reduced by 30-40% the vasoconstrictor responses to ET-1 and ANG II. Inhibition of 12-LOX with baicalein and 5- and 12-LOX with 5,8,11-eicosatriynoic acid attenuated ANG II-induced renal vasoconstriction by approximately 40-60% but did not affect responses to ET-1. In contrast, 12,12-dibromododec-11-enoic acid (DBDD), an inhibitor of the CYP omega/omega 1-hydroxylase pathway, diminished ET-1-induced renal vasoconstriction by 30-40%, an effect reproduced by depletion of CYP enzymes with CoCl2. Neither DBDD nor CoCl2 affected renal vasoconstriction elicited by ANG II. ET-1 increased efflux of 19- and 20-hydroxyeicosatetraenoic acid, an effect reduced by DBDD. Thus products of the COX and CYP pathways contribute to the renal vasoconstrictor response to ET-1, whereas COX- and LOX-derived eicosanoids contribute to the response to ANG II, accounting for > or = 80% of the vasoactivity of the peptides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249563     DOI: 10.1152/ajpregu.1997.273.1.R293

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  16 in total

1.  Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE.

Authors:  D Sacerdoti; M Balazy; P Angeli; A Gatta; J C McGiff
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

3.  Cytosolic Phospholipase A2α Is Essential for Renal Dysfunction and End-Organ Damage Associated With Angiotensin II-Induced Hypertension.

Authors:  Nayaab S Khan; Chi Young Song; Shyamala Thirunavukkarasu; Xiao R Fang; Joseph V Bonventre; Kafait U Malik
Journal:  Am J Hypertens       Date:  2015-06-04       Impact factor: 2.689

Review 4.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 5.  Cytochrome P450 and Lipoxygenase Metabolites on Renal Function.

Authors:  John D Imig; Md Abdul Hye Khan
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

6.  Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage.

Authors:  L Hacein-Bey; D R Harder; H T Meier; P N Varelas; N Miyata; K K Lauer; J F Cusick; R J Roman
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

Review 7.  Vascular actions of 20-HETE.

Authors:  Samantha L Hoopes; Victor Garcia; Matthew L Edin; Michal L Schwartzman; Darryl C Zeldin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-03-23       Impact factor: 3.072

Review 8.  Potential role of CYP1B1 in the development and treatment of metabolic diseases.

Authors:  Fei Li; Weifeng Zhu; Frank J Gonzalez
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

9.  CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow.

Authors:  Jonathan S Williams; Paul N Hopkins; Xavier Jeunemaitre; Nancy J Brown
Journal:  J Hypertens       Date:  2011-10       Impact factor: 4.844

Review 10.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.